芪药消渴胶囊联合吡格列酮治疗2型糖尿病的临床研究

Clinical study on Qiyao Xiaoke Capsules combined with pioglitazone in treatment of type 2 diabetes

目的探讨芪药消渴胶囊联合吡格列酮治疗2型糖尿病的临床效果。方法选取2016年3月—2018年3月北京远洋健康博雅诊所有限公司收治的2型糖尿病患者98例,随机分成对照组(49)和治疗组(49)。对照组口服盐酸吡格列酮片,1片/次,1次/d。治疗组在对照组基础上口服芪药消渴胶囊,6粒/次,3次/d。两组均连续治疗8周。观察两组患者临床疗效,同时比较治疗前后两组患者血糖、血脂、胰岛素、血流变参数、白介素-1β(IL-1β)、活性氧(ROS)、还原型谷胱甘肽(GSH)和C反应蛋白(CRP)水平。结果治疗后,对照组临床有效率为79.6%,显著低于治疗组的93.9%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组空腹血糖(FPG)、糖化血红蛋白(HbA1c)、三酰甘油(TG)/高密度脂蛋白胆固醇(HDL-C)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)血浆水平及血流变参数红细胞变形指数(EDI)、血浆黏度(PV)和红细胞聚集指数(EAI)值均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05),且治疗组患者上述参数明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组血清IL-1β、ROS、CRP水平均显著降低,血清GSH水平显著升高,同组治疗前后比较差异具有统计学意义(P<0.05),且治疗组患者IL-1β、ROS、GSH和CRP水平明显优于对照组(P<0.05)。结论芪药消渴胶囊联合吡格列酮治疗2型糖尿病可有效控制患者血糖水平,纠正脂代谢紊乱,增强胰岛素敏感性,疗效确切。

Objective To investigate the clinical effect of Qiyao Xiaoke Capsules combined with pioglitazone in treatment of type 2 diabetes. Methods Patients(98 cases) with type 2 diabetes in Yuanyang Healthcare Boya Clinnique Ltd. from March 2016 to March2018 were randomly divided into control(49 cases) and treatment(49 cases) groups. Patients in the control group were po administered with Pioglitazone Hydrochloride Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Qiyao Xiaoke Capsules on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the blood glucose, blood lipid, insulin parameters, hemorheological parameters,IL-1β, ROS, GSH, and CRP levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 79.6%, which was significantly lower than 93.9% in the treatment group, and there were differences between two groups(P < 0.05). After treatment, the plasma FPG, HbA1c, TG/HDL-C, FINS and HOMA-IR levels, EDI, PV, and EAI value in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05), and these indexes levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the serum IL-1β, ROS, and CRP concentration in two groups was significantly decreased, but serum GSH content was significantly increased, and the difference was statistically significant in the same group(P < 0.05). And the serum IL-1β, ROS, GSH, and CRP content in the treatment group was significantly better than those in the control group(P < 0.05).Conclusion Qiyao Xiaoke Capsules combined with pioglitazone in treatment of type 2 diabetes can effectively control the blood glucose level, correct lipid metabolism disorder, enhance insulin sensitivity, and which has definite curative effect.